Nasdaq:PRVA
Privia Health Group, Inc.
Privia Health Group delivers specialized EHR solutions to US hospitals, achieving a return to profitability with $29.7M net income in 2025.
Key Metrics
Investment Thesis
Bull Case
Investors may find value in PRVA due to its successful turnaround from net loss to strong profitability, showcasing effective cost management and revenue growth strategies. The company's niche focus on acute care EHR solutions offers a defensible market position with high customer retention rates and predictable recurring cash flows. Recent acquisition activity suggests strategic expansion that could drive future organic growth and product differentiation.
Bear Case
Concerns regarding the sustainability of revenue growth exist given the saturation of the acute care EHR market and potential headwinds from large competitor offerings. The company maintains a significant retained earnings deficit of -$156.3M, which may limit financial flexibility for future aggressive expansion or R&D investments. Heavy reliance on accounts receivable of $400.9M versus lower cash reserves requires careful monitoring of working capital efficiency and collection cycles.
About Privia Health Group, Inc.
Privia Health Group, Inc. (PRVA) is a leading provider of healthcare information technology solutions serving acute care hospitals across the United States. The company specializes in electronic health record (EHR) systems, specifically its proprietary Prism platform, designed to improve operational efficiency and patient outcomes. With total revenue reaching $2.12B in 2025, Privia focuses on delivering scalable cloud-based services that help healthcare organizations manage complex data workflows.
Analysis
Management Discussion
Privia reported strong financial recovery with revenue growing from $1.36B in 2022 to $2.12B in 2025, reflecting successful product adoption and market penetration. The company achieved consistent profitability, posting net income of $29.7M in 2025 compared to a loss of $12.1M in 2022, demonstrating improved operational leverage. Significant investments in acquisitions totaling $180.4M were made to enhance product capabilities, though this resulted in negative investing cash flow of -$181.6M during the period.
Industry Overview
The healthcare IT industry is experiencing robust growth driven by the shift to digital transformation, cloud adoption, and the need for interoperable patient data systems. Competition remains fierce between specialized vendors and large enterprise players, with pricing pressure increasing as demand stabilizes post-pandemic. Regulatory mandates on data exchange continue to drive innovation but also increase compliance burdens for all market participants.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1.36B | $1.66B | $1.74B | $2.12B |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $1.36B | $1.66B | $1.74B | $2.12B |
| Operating Expenses | $1.38B | $1.64B | $1.72B | $2.09B |
| Operating Income | $-19.1M | $20.6M | $17.0M | $34.2M |
| G&A | $129.6M | $109.6M | $126.2M | $138.2M |
| Marketing | $19.7M | $24.7M | $26.4M | $27.1M |
| Stock-Based Comp | $67.4M | $37.1M | $56.7M | $71.1M |
| D&A | $4.6M | $6.5M | $7.3M | $9.9M |
| Depreciation | $1.2M | $1.2M | $1.1M | $739.0K |
| Amortization | $3.4M | $5.4M | $6.2M | $9.2M |
| Other OpEx | $1.23B | $1.50B | $1.57B | $1.92B |
| Non-Operating Income | $542.0K | $8.4M | $10.9M | $9.7M |
| Interest Expense | $500.0K | — | — | — |
| Pre-Tax Income | $-18.6M | $29.0M | $27.9M | $43.9M |
| Income Tax | $-6.5M | $8.0M | $10.8M | $14.2M |
| Continuing Ops | $-12.1M | $21.0M | $17.0M | $29.7M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-12.1M | $21.0M | $17.0M | $29.7M |
| Minority Interest | $-3.5M | $-2.1M | $2.7M | $6.8M |
| Net to Common | $-8.6M | $23.1M | $14.4M | $22.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $552.0M | $700.8M | $834.8M | $911.0M |
| Cash & Equivalents | $348.0M | $389.5M | $491.1M | $479.7M |
| Accounts Receivable | $189.6M | $290.8M | $316.2M | $400.9M |
| Prepaid Expenses | $14.4M | $20.5M | $27.5M | $30.4M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $240.9M | $299.1M | $301.0M | $458.4M |
| PP&E (Net) | $3.4M | $2.3M | $1.2M | $504.0K |
| Goodwill | $126.9M | $138.7M | $141.6M | $209.8M |
| Operating Leases | $8.1M | $6.6M | $4.8M | $8.8M |
| Other LT Assets | $102.4M | $151.4M | $153.3M | $239.2M |
| Total Assets | $792.8M | $999.9M | $1.14B | $1.37B |
| Current Liabilities | $264.3M | $387.0M | $449.1M | $568.5M |
| Accounts Payable | $6.7M | $7.9M | $9.8M | $8.0M |
| Current Leases | $3.0M | $3.0M | $2.6M | $2.2M |
| Other Current Liab | $254.5M | $376.0M | $436.8M | $558.3M |
| Long-Term Liabilities | $9.5M | $5.6M | $3.2M | $9.9M |
| LT Operating Leases | $8.5M | $5.2M | $3.0M | $7.3M |
| Other LT Liab | $1.0M | $313.0K | $153.0K | $2.6M |
| Total Liabilities | $273.8M | $392.5M | $452.3M | $578.4M |
| Shareholders' Equity | $519.0M | $607.4M | $683.4M | $790.9M |
| Paid-In Capital | $714.6M | $753.9M | $813.2M | $892.3M |
| Retained Earnings | $-216.7M | $-193.6M | $-179.2M | $-156.3M |
| Total L&E | $792.8M | $999.9M | $1.14B | $1.37B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-12.1M | $21.0M | $17.0M | $29.7M |
| Non-Cash Adjustments | $-19.6M | $-46.4M | $44.7M | $80.3M |
| Working Capital Changes | $78.9M | $106.2M | $47.6M | $53.4M |
| Cash from Operations | $47.2M | $80.8M | $109.3M | $163.4M |
| Capital Expenditures | $104.0K | $113.0K | — | — |
| Cash from Investing | $-104.0K | $-43.0M | $-12.0M | $-181.6M |
| Cash from Financing | $-19.7M | $3.7M | $4.3M | $6.7M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $27.4M | $41.5M | $101.6M | $-11.5M |
| Beginning Cash | $320.6M | $348.0M | $389.5M | $491.1M |
| Ending Cash | $348.0M | $389.5M | $491.1M | $479.7M |
Frequently Asked Questions
How does Privia Health Group, Inc. make money?
The company's revenue is primarily driven by its Prism electronic health record platform sold to acute care hospital systems, supplemented by ancillary services such as practice management software and data analytics tools that integrate directly with the core EHR ecosystem.
What are the main risks for PRVA?
The healthcare technology sector faces intense competition from large incumbents like Epic and Oracle, which could pressure pricing power or market share. Regulatory changes in healthcare data privacy and interoperability standards pose potential compliance costs and implementation delays. Dependence on a concentrated customer base of acute care hospitals creates exposure to specific payer reimbursement cycles and economic downturns affecting hospital capital expenditure.
What is PRVA's competitive advantage?
Privia possesses a deep proprietary knowledge of acute care workflows embedded within its Prism platform, creating high switching costs for hospital clients. The company benefits from a strong recurring revenue model driven by long-term contracts and a dedicated support infrastructure that minimizes client downtime. Its focus on niche acute care specialization differentiates it from broader enterprise EHR competitors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.